Compugen (NASDAQ:CGEN) Upgraded by StockNews.com to Buy

StockNews.com upgraded shares of Compugen (NASDAQ:CGEN) from a hold rating to a buy rating in a report issued on Thursday.

Separately, Truist Financial cut their price target on Compugen from $5.00 to $4.00 and set a buy rating on the stock in a research note on Tuesday, May 21st.

Compugen Price Performance

Shares of NASDAQ:CGEN opened at $1.84 on Thursday. Compugen has a one year low of $0.53 and a one year high of $3.03. The company has a market cap of $159.40 million, a price-to-earnings ratio of -9.68 and a beta of 2.60. The firm has a 50 day simple moving average of $1.80 and a 200 day simple moving average of $2.13.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.06. The company had revenue of $6.70 million for the quarter, compared to analyst estimates of $2.68 million. During the same quarter last year, the company posted ($0.11) earnings per share. As a group, analysts expect that Compugen will post 0.05 EPS for the current year.

Hedge Funds Weigh In On Compugen

Hedge funds have recently modified their holdings of the business. Heron Bay Capital Management bought a new stake in shares of Compugen in the 1st quarter valued at about $32,000. Squarepoint Ops LLC lifted its stake in shares of Compugen by 23.4% in the second quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock worth $144,000 after acquiring an additional 16,253 shares during the period. Secure Asset Management LLC acquired a new position in shares of Compugen in the 2nd quarter worth approximately $69,000. ARK Investment Management LLC lifted its position in shares of Compugen by 4.7% in the 2nd quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock worth $1,850,000 after purchasing an additional 48,979 shares during the period. Finally, Rothschild Investment LLC bought a new stake in shares of Compugen in the 2nd quarter valued at $380,000. Institutional investors and hedge funds own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.